Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ IN PLASTIC CONTAINER versus KEFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ IN PLASTIC CONTAINER versus KEFLEX.
FORTAZ IN PLASTIC CONTAINER vs KEFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
250-500 mg orally every 6 hours; maximum 4 g/day.
None Documented
None Documented
1.8 hours in normal adults; prolonged to 3-5 hours in neonates and 10-30 hours in severe renal impairment (CrCl <10 mL/min)
0.5–1.2 hours in patients with normal renal function (CrCl >50 mL/min); prolonged to >20 hours in ESRD.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%)
Primarily renal (90% or more unchanged via glomerular filtration and tubular secretion); small amounts biliary/fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic